October 2022
Volume 11, Issue 10
Open Access
Erratum  |   October 2022
Erratum in: Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury
Translational Vision Science & Technology October 2022, Vol.11, 30. doi:https://doi.org/10.1167/tvst.11.10.30
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Erratum in: Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury. Trans. Vis. Sci. Tech. 2022;11(10):30. doi: https://doi.org/10.1167/tvst.11.10.30.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Erratum in: “Topical Losartan and Corticosteroid Additively Inhibit Corneal Stromal Myofibroblast Generation and Scarring Fibrosis After Alkali Burn Injury” by Lycia Pedral Sampaio, Guilherme S. L. Hilgert, Thomas Michael Shiju, Marcony R. Santhiago, and Steven E. Wilson (Transl Vis Sci Technol. 2022;11(7):9), https://doi.org/10.1167/tvst.11.7.9
The authors discovered that the stock medication used in preparation of the topical 0.8% losartan in balanced salt solution for this study contained “excipients” used in the manufacture of losartan tablets. As a result, the true final concentration was 0.2% losartan in the balanced salt solution used for the topical application of losartan in this study; 0.8 mg/mL losartan has now been changed to 0.2 mg/mL losartan throughout the article online. 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×